KDM1A and leukemia: Currently, TCP-derived LSD1 inhibitors such as ORY-1001, IMG7289, GSK2879552 and INCB059872 (Figure 5A) alone or in combination with other agents such as all-trans retinoic acid (ATRA), cytarabine or azacitidine, etc., are undergoing clinical assessments mainly for treatment of leukemias and solid tumors (Lee et al., 2016; Somervaille et al., 2016; Zheng et al., 2016).